ArticleLipids in health and disease2009
Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small intestine.
Article in Lipids in health and disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Effects of HA1, a probucol analogue, and APOC3 siRNA on lipoprotein and amyloid-β metabolism and neurovascular dysfunction in type 2 diabetic mice.Frontiers in pharmacology · 2026Article
- Comparison of amyloid and tau pathology in the small and large intestines of individuals with Alzheimer's disease, Parkinson's disease, and Dementia with Lewy bodies.microPublication biology · 2026Article
- Tuft Cells in the Gut Limit Cognitive Disorders by Regulating Gut Homeostasis.Cellular and molecular gastroenterology and hepatology · 2026Article
- Differential effects of S-allyl cysteine and cannabidiol on enterocytic and plasma amyloid-β in db/db diabetic mice.Scientific reports · 2025Article
- Molecular Simulation of the Binding of Amyloid Beta to Apolipoprotein A-I in High-Density Lipoproteins.International journal of molecular sciences · 2025Article
- Fecal Microbiota Transplantation Improves Cognitive Function of a Mouse Model of Alzheimer's Disease.CNS neuroscience & therapeutics · 2025Article
- Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model.Frontiers in pharmacology · 2024Article
- Peripheral metabolism of lipoprotein-amyloid beta as a risk factor for Alzheimer's disease: potential interactive effects of APOE genotype with dietary fats.Genes & nutrition · 2023Review
- Neurodegenerative Microbially-Shaped Diseases: Oxidative Stress Meets Neuroinflammation.Antioxidants (Basel, Switzerland) · 2022Review
- Does the Gut Microbial Metabolome Really Matter? The Connection between GUT Metabolome and Neurological Disorders.Nutrients · 2022Review
- Nutrient Sensing via Gut inInternational journal of molecular sciences · 2022Review
- Gastrointestinal Changes and Alzheimer's Disease.Current Alzheimer research · 2022Review
- A New Hypothesis for Alzheimer's Disease: The Lipid Invasion Model.Journal of Alzheimer's disease reports · 2022Article
- Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid Involvement.Pharmaceutical research · 2021Review
- Gut Microbiota as a Potential Player in Mn-Induced Neurotoxicity.Biomolecules · 2021Review
- The Microbiota-Gut-Brain Axis and Alzheimer Disease. From Dysbiosis to Neurodegeneration: Focus on the Central Nervous System Glial Cells.Journal of clinical medicine · 2021Review
- The differential effects of fatty acids on enterocytic abundance of amyloid-beta.Lipids in health and disease · 2019Article
- Microbiome Influence in the Pathogenesis of Prion and Alzheimer's Diseases.International journal of molecular sciences · 2019Review
- Temporal progression of Alzheimer's disease in brains and intestines of transgenic mice.Neurobiology of aging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmyloid-beta is recognized as the major constituent of senile plaque found in subjects with Alzheimer's disease. However, there is increasing evidence that in a physiological context amyloid-beta may serve as regulating apolipoprotein, primarily of the triglyceride enriched lipoproteins. To consider this hypothesis further, this study utilized an in vivo immunological approach to explore in lipogenic tissue whether amyloid-beta colocalizes with nascent triglyceride-rich lipoproteins.
resultsIn murine absorptive epithelial cells of the small intestine, amyloid-beta had remarkable colocalization with chylomicrons (Manders overlap coefficient = 0.73 +/- 0.03 (SEM)), the latter identified as immunoreactive apolipoprotein B. A diet enriched in saturated fats doubled the abundance of both amyloid-beta and apo B and increased the overlap coefficient of the two proteins (0.87 +/- 0.02). However, there was no evidence that abundance of the two proteins was interdependent within the enterocytes (Pearson's Coefficient < 0.02 +/- 0.03), or in plasma (Pearson's Coefficient < 0.01).
conclusionThe findings of this study are consistent with the possibility that amyloid-beta is secreted by enterocytes as an apolipoprotein component of chylomicrons. However, secretion of amyloid-beta appears to be independent of chylomicron biogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.